This is a rare condition that affects the skin. It's linked to a specific type of cancer called Lynch Syndrome. People with Muir-Torre Syndrome often develop unusual skin growths called sebaceous gland tumors. It can also increase the risk of other cancers in the colon, uterus, and other parts of the body.
Every report comes from a Lived member, sent anonymously.
Have you had Mohs Surgery for Muir-Torre Syndrome?
Muir-Torre syndrome is an inherited condition that raises the risk of two kinds of growth: uncommon skin tumors that form in the skin's oil glands (sebaceous glands), and cancers of internal organs, most often the colon. It is a variant of Lynch syndrome, a better-known inherited condition that increases the risk of colorectal cancer, endometrial cancer (cancer of the lining of the uterus) and several other cancers. Doctors use the name Muir-Torre syndrome when a person has at least one sebaceous skin tumor and at least one Lynch-related internal cancer, whether they appear at the same time or years apart. The skin tumors are usually small yellowish, pink or skin-colored bumps, most often on the face, scalp or neck, though they can also appear on the trunk. Most are benign growths such as sebaceous adenomas, but some are sebaceous carcinomas, a cancer of oil-gland cells. Fast-growing, dome-shaped bumps called keratoacanthomas can also occur. These skin findings matter because they can be the first visible sign of an inherited cancer risk, sometimes showing up before any internal cancer has been found. About 9 in 100 people with Lynch syndrome develop them.
Muir-Torre syndrome is caused by an inherited change in one of the genes that fix copying mistakes in DNA, known as mismatch repair genes. A gene called MSH2 is involved in most cases. When this repair system does not work properly, errors build up each time cells divide, and some cells eventually grow into tumors. Because the inherited change is present in every cell, tumors can arise in different organs over a lifetime. The usual form is passed down in an autosomal dominant pattern: a parent who carries the change has a 50% chance of passing it to each child, whether son or daughter. Carrying the change raises cancer risk but does not mean a person will develop cancer, and relatives who share the same change can be affected very differently. A less common form, sometimes called type 2, does not show the same repair defect in its tumors and appears to require a changed gene from both parents. It is much less well understood. Nothing a person does causes the syndrome. Sun exposure adds to the risk of ordinary skin cancers, which are also seen in people with Lynch syndrome. In people who take immune-suppressing medicines after an organ transplant, sebaceous tumors have sometimes appeared quickly, and in several reported cases this is what first revealed the syndrome.
Diagnosis often starts with a biopsy of a skin bump. Finding a sebaceous adenoma, sebaceoma (a related benign tumor) or sebaceous carcinoma prompts a closer look, especially when there is more than one, when it appears away from the head and neck, or when the person or close relatives have had colon, uterine or other Lynch-related cancers. Two oil-gland findings do not point to the syndrome on their own: sebaceous hyperplasia, a very common harmless enlargement of oil glands, and sebaceous carcinoma of the eyelid, a true oil-gland cancer that still needs treatment. The pathologist can stain the tumor for the four mismatch repair proteins, a test called immunohistochemistry. If one or more proteins are missing, an inherited repair defect becomes more likely, but the test also flags many tumors in people who do not have the syndrome, because the same loss can occur in the tumor alone. Clinicians may also use a scoring tool that weighs age when the first sebaceous tumor appeared, how many there have been, and personal and family history of Lynch-related cancer to decide who needs genetic testing. Confirmation comes from a genetic test, usually on blood or saliva, that looks for an inherited change in a mismatch repair gene. This is best arranged with a genetic counselor, who also reviews the family history in detail. The final diagnosis rests on the whole picture: skin tumors, internal cancers, tumor testing and genetic results. When the skin tumor is the first finding, the diagnosis creates a chance to look for internal cancers that have not yet caused symptoms.
There is no treatment that removes the inherited risk, and there are no management guidelines written specifically for Muir-Torre syndrome. Care follows the approach used for Lynch syndrome and has two aims: removing tumors as they appear, and finding internal cancers early or preventing them. Skin tumors are usually removed surgically, which treats them and lets a pathologist confirm what they are. Sebaceous carcinomas need complete removal, and those near the eye may need specialized surgery to protect the eyelid. Regular full-body skin exams with a dermatologist help catch new growths, and sun protection lowers the risk of ordinary skin cancers. For people who keep developing many skin tumors, some dermatologists consider a low dose of an oral retinoid (a vitamin A-related prescription medicine) such as isotretinoin to slow new growths. The support for this comes only from case reports and expert opinion, so it is a decision to weigh carefully with a specialist. Isotretinoin causes severe birth defects, so it cannot be taken during pregnancy and requires reliable contraception for anyone who could become pregnant. Cancer screening is the core of care. Colonoscopy every 1 to 2 years, usually starting in the 20s for people with Lynch syndrome, has been shown to lower both the chance of developing colorectal cancer and the chance of dying from it, partly because precancerous polyps can be removed during the exam. Depending on the gene involved and the family history, the care team may add other checks, such as upper endoscopy (a camera exam of the stomach and upper small intestine) or yearly urine tests for urinary tract cancer. For women, surgery to remove the uterus and ovaries effectively prevents endometrial and ovarian cancer, and the timing is usually discussed around family plans, since removing both ovaries before natural menopause brings on menopause right away. Some people with Lynch syndrome take aspirin to lower colorectal cancer risk, based on a trial in which people who took it for at least two years had fewer colorectal cancers. Whether that makes sense for an individual depends on their other health conditions and aspirin's own risks. Internal cancers are treated according to their type and stage, often with surgery. Many Lynch-related cancers have the same repair defect, which can make them respond well to immunotherapy drugs called checkpoint inhibitors, such as pembrolizumab (Keytruda), when the cancer is advanced.
Muir-Torre syndrome is lifelong, but having it does not mean a person will develop every cancer linked to it, and the course varies widely, even within one family. Sebaceous tumors and the first internal cancer typically appear around age 50, although they can occur much earlier or later. New skin growths may keep appearing over the years, so having them checked and removed becomes a regular part of life for many people. Sebaceous carcinomas in this syndrome tend to behave less aggressively than the same cancer in people without it, and the associated internal cancers often do as well. Day to day, the main commitment is a screening schedule: colonoscopies, skin checks and any other tests the care team recommends. Care is often shared among a dermatologist, a gastroenterologist, a gynecologist for women, and a genetics team, and it helps to have one clinician who keeps the overall plan up to date as recommendations change. Keeping to the schedule is what makes early detection possible. The diagnosis also matters for relatives. Once a specific gene change is found, parents, brothers, sisters and children can be tested for that exact change. Relatives who carry it can start screening early, while those who test negative can learn that they do not share the family's inherited risk. A genetic counselor can help with how to share the news and with questions about family planning.
Ask a dermatologist or primary care clinician to look at a new yellowish, pink or skin-colored bump, especially if there is more than one, or if you or close relatives have had colon, uterine or other Lynch-related cancers. If a sebaceous tumor is removed, ask whether it was tested for mismatch repair proteins and whether genetic counseling is recommended. If you already have the syndrome, contact your care team soon about a skin growth that grows quickly, bleeds or opens into a sore, and about symptoms that can signal an internal cancer: blood in the stool, a change in bowel habits that lasts more than a few days, unexplained weight loss, abnormal vaginal bleeding, or blood in the urine. Let your care team know before an organ transplant or long-term immune-suppressing treatment, since these can speed up skin tumor growth.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Muir-Torre Syndrome is like, what's helped you, or ask the community a question.